What happened. On July 22, 2026, the FDA approved zidesamtinib, marketed as Jideytro by Nuvalent, Inc., for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer who received at least one prior ROS1 tyrosine kinase inhibitor. The approval, posted by FDA on July 24, was based on ARROS-1, a multicenter, single-arm, open-label, multi-cohort trial in previously treated patients with locally advanced or metastatic ROS1-positive NSCLC.
The efficacy population included 117 patients: 59 who received one prior ROS1 TKI and 58 who received two or more prior ROS1 TKIs, including lorlatinib, repotrectinib, and/or taletrectinib. In the overall efficacy population, confirmed overall response rate was 44% with a 95% confidence interval of 34 to 53. Among responders, 82% had a duration of response of at least 6 months and 69% had a duration of response of at least 12 months. ORR was 49% in patients with one prior ROS1 TKI and 38% in those with two or more prior ROS1 TKIs.
The label carries warnings and precautions for central nervous system adverse reactions, QTc interval prolongation, interstitial lung disease or pneumonitis, skeletal fractures, myalgia with creatine phosphokinase elevation, pancreatic toxicity, and embryo-fetal toxicity. The recommended dose is 100 mg orally once daily, with or without food, until disease progression or unacceptable toxicity. FDA said the review used the Real-Time Oncology Review pilot program and the Assessment Aid, and that the application was approved two months ahead of the FDA goal date. Zidesamtinib also received orphan drug designation.
Why it matters. Nuvalent now has an FDA-approved product in a molecularly defined lung cancer segment where patients have already been exposed to at least one ROS1 TKI, and in many cases more than one. That matters because the filing shows activity not only in the broader study population but also in the subgroup that had received two or more prior ROS1 TKIs. For oncologists and investors, that supports a clear post-prior-TKI positioning rather than an early-line story. For a clinical refresher on treatment context, see ClinicalRx.ai.
The filing also reinforces how FDA is still using expedited oncology review tools when an application fits the profile. Approval two months ahead of the goal date, alongside use of RTOR and Assessment Aid, suggests the agency saw a package it could process efficiently. Then there is uptake. Commercial and clinical, against the label’s safety warnings, especially central nervous system adverse reactions, QTc interval prolongation, and interstitial lung disease or pneumonitis.
One likely implication for payers is a relatively focused management approach given the biomarker-defined population and prior-treatment requirement. For broader oncology market access and benefit design implications, see PharmaBenefits.ai.